It’s a brain disease,” a prominent obesity doctor explained on a “60 Minutes” episode about the drugs. “Obesity is disease” ...

Certain blockbuster weight-loss drugs have been found to protect the heart in significant ways, and new research suggests ...

A woman who used Wegovy and Ozempic says the drugmaker didn't adequately warn her, or other patients, of serious side effects ...

Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.

In July, the U.S. Food and Drug Administration warned that people are overdosing on compounded semaglutide injectable ...

A shortage and user error are being blamed for a massive spike in calls to the Utah Poison Control Center over weight loss ...

Ozempic maker Novo Nordisk has developed a pill that can cause weight loss of up to 13% in three months, according to new ...

You don't often see a "science day" in a Philadelphia courtroom. But that's exactly what happened last week in a potentially ...

A woman who used the semaglutide drugs Wegovy and Ozempic to lose weight and treat diabetes says the drugmaker didn’t ...

A new study conducted by professional services firm Aon found employer health care expenditures are projected to surge 9% in 2025 to more than $16,000 per employee, markedly higher than the 6.5% ...

Plus: GLP-1 drugs like Ozempic have potential to treat cancer, COVID-19, heart disease, and many other diseases.

Businesses can take proactive steps now to best position themselves for a competitive advantage in the face of the seismic shift these medications will have on the industry.